Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase.

Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.

Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.

Kazia Therapeutics is pleased to make its May 2018 newsletter available to investors via this link.

A breakthrough new treatment for ovarian cancer that aims to stop the disease returning by killing off the cancer’s stem cells is undergoing safety trials in Australia.

A prominent Australian oncology researcher says ovarian cancer patients are losing out as badly-needed funds and clinical attention is focused on more prominent – yet not as deadly – women’s diseases.

Kazia was delighted recently to have the members of our Scientific Advisory Board gather in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer. Stuart Roberts, Senior Analyst at NDF Research took the opportunity to conduct wide-ranging interviews with each of the SAB members, which provide rich insights into their work. 

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing a new therapy called GDC-0084 to treat the rare and deadly brain cancer, glioblastoma multiforme (GBM).